Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


PDA: Services review could increase your commissioning power

The upcoming assessment of MURs and other pharmacy services could bring benefits to pharmacists, PDA chair Mark Koziol said in a C+D podcast


NHS England’s review of pharmacy services could redistribute commissioning power across the sector, the Pharmacists' Defence Association (PDA) has said.

The wide-ranging review, scheduled to begin this month, “could work in favour of the profession”, PDA chair Mark Koziol told C+D in an exclusive interview earlier this month.

NHS England said the review, due to start later this month, was requested by England's chief pharmaceutical officer Keith Ridge to advise him on how clinical services can be “modernised” to ensure pharmacy meets the “changing shape and demands of healthcare”.

Mr Koziol told C+D that the review “might help to underpin professionalism”. “Some commissioning might move towards pharmacists and group practices of pharmacists,” he said in a C+D podcast recorded on May 12.

A second take on how pharmacy works

The review offers a “second take” on “how community pharmacy works”, Mr Koziol said. The PDA will use the review to reemphasise its strategy for “individual pharmacists to have a greater say in how services are provided”.

“We’re not saying, ‘forget bricks-and mortar contractors and switch it all to pharmacists’. We’re saying that both of these vehicles have a role in the new health service,” he said.

“We’re the only voice that’s articulating that because why would turkeys vote for Christmas?” he added. 

NHS England told C+D earlier this month that it has not ruled out reviewing medicines use review (MUR) and new medicine service (NMS) fees as part of its review.

You can listen to C+D's full interview with Mr Koziol in the podcast below:


Do you agree with Mr Koziol?

We want to hear your views, but please express them in the spirit of a constructive, professional debate. For more information about what this means, please click here to see our community principles and information

Related Content


Pharmacy Manager

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts